Delivery Order SPE2DB20D9331-SPE2DB26FL0C7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count units. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a $21,177.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in quantities of 30. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 20, 2025. The contract covers the supply of Nuplazid 34 mg capsules in quantities of 30, with a firm fixed-price structure and an ultimate completion date of September 11, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete on an...
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packages). The award, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, utilizes firm fixed-price pricing and does not include a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. on August 12, 2025, for the supply of Nuplazid 34 mg capsules in quantities of 30. This firm fixed-price delivery order, which carries an ultimate completion date of September 3, 2025, represents a direct procurement with no set-aside designation. The order will be fulfilled from the vendor's location in Park Ridge, Illinois, and supports the pharmaceutical supply needs of Department...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- The Defense Logistics Agency issued a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count packaging. This delivery order was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, utilizing firm fixed-price pricing with no set-aside designation. The order represents a discrete fulfillment under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) with an ultimate completion date of September 26, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its primary location. This delivery order is issued...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for Nuplazid 34 mg capsules (30-count packaging) valued at $10,375.53. This firm fixed-price delivery order, which carries no set-aside designation, represents a specific fulfillment under the company's broader Indefinite Delivery Contract with DLA. The contract will be completed by November...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB26FL0C7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,373.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 10 mg tablets (30-count packages). The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries a firm fixed-price contract type with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will perform the work at its Park Ridge, Illinois facility and will serve as the sole prime contractor with no identified subcontractors on this delivery order. This delivery order is issued under DMS Pharmaceutical Group Inc.'s single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs for Department of Defense healthcare facilities worldwide. The underlying IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables. This delivery order for Nuplazid represents one of numerous orders DMS Pharmaceutical Group has fulfilled through this program, demonstrating the company's critical role in the federal military medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 10/27/25 |